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ABSTRACT 
Extant literature on firm-university collaboration has emphasized two different strategies that 
firms in science based industries adopt in order to source scientific knowledge and expertise. 
On the one hand, firms engage in direct research collaborations with universities. On the other 
hand, firms establish indirect, mediated, ties to universities by engaging in research 
collaborations with dedicated biotech firms (DBFs) that are themselves strongly linked to 
universities - with the DBF taking the role of ‘broker’. We argue that the relative benefits of 
direct and mediated ties depend on the extent to which firms have organized their R&D to 
facilitate the absorption, assimilation, transformation and exploitation of scientific knowledge, 
which we coin ‘scientific absorptive capacity’. Drawing on patent and publication data in a 
panel of 33 vertically integrated pharmaceutical firms, we find that direct university 
collaboration is more beneficial for firms with relatively high scientific absorptive capacity, 
while only mediated ties are associated with greater innovative performance for firms with 
relatively low scientific absorptive capacity. The latter association is reduced if the mediated 
ties are with top universities. Our findings are suggestive of the importance of a ‘fit’ between 
the nature of a firm’s R&D organization and its strategy to access scientific knowledge. 
 
Keywords: R&D collaboration, alliance portfolios, industry-science linkages, scientific 
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INTRODUCTION 
Knowledge-intensive industries in general and science-based industries in particular, have 
been characterized by an intensification of the interactions between universities and firms 
(e.g. Hall et al., 2000; Cassiman et al., 2008). Firms increasingly look towards public science 
as one of the key sources for rapid and privileged access to new knowledge (Cockburn and 
Henderson, 2000; Zucker, et al., 1998; Mowery, 1998; Bruneel et al., 2010, Leten et al. 2011). 
This puts the issue of external knowledge sourcing from universities high on the corporate 
agenda, in order to keep at the forefront of the creation of new, state-of-the-art knowledge 
(Cohen et al., 2002; Mowery and Nelson, 1999; Balconi and Laboranti, 2006). Prior research 
on industry-science linkages has shown that research collaboration with university scientists is 
an important means for effective scientific knowledge sourcing and that this may yield a 
positive effect on a firm’s innovative performance (Zucker and Darby, 2001; Zucker, et al., 
2002; George et al, 2002; Cassiman et al., 2008). More specifically, such business-university 
R&D collaboration may enhance firms’ capacity to generate high impact technologies and 
introduce new products to the market (Belderbos et al., 2004; Faems et al., 2005; Cassiman et 
al., 2008).  
 
Extant literature on firm-university collaboration has emphasized two different strategies to 
source key scientific expertise. In the industry-science literature, the importance has been 
stressed of direct collaboration with universities (Cohen et al., 2002). The idea is that in 
knowledge-intensive industries it is important for firms to collaborate directly with 
universities in order to source state-of-the-art expertise developed at public research 
organizations and universities (Zucker and Darby, 2001; Zucker et al., 2002; Zucker and 
Darby, 2002; Cassiman et al., 2008). Direct collaboration with universities appears to be the 
realm of firms with substantial internal R&D capabilities (Belderbos et al., 2004). Active 
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involvement in scientific research (collaboration) is often conditional on the availability of 
human capital and the adoption of specialised organizational practices and routines in R&D 
(Gambardella, 1992; Cockburn et al, 1999).  
 
On the other hand, studies in the innovation and strategic collaboration literature have 
emphasized that pharmaceutical firms collaborate with entrepreneurial dedicated biotech 
firms (DBFs) that are themselves strongly linked to universities and embedded in academic 
networks (Liebeskind et al., 1996; Powell et al., 1996; Zucker et al., 1998; George et al., 
2002; Stuart et al., 2007). Hence, pharmaceutical firms also establish indirect, or ‘DBF-
mediated’, ties to universities. Whereas both direct and indirect ties to universities have 
received attention in extant literature, there still is limited insight into the relative benefits of 
the two collaboration strategies. Addressing this issue forms the research objective of the 
current study.  
 
The main premise of this paper is that the relative benefits of direct and mediated ties depend 
on the heterogeneous capabilities of pharmaceutical firms. We argue that differential 
performance benefits of the two collaboration strategies depend on the extent to which firms 
have strategically organized their R&D to facilitate the absorption, assimilation, 
transformation and exploitation of scientific knowledge. This is a specific form of absorptive 
capacity (Cohen and Levinthal, 1990; Zahra and George, 2002), i.e. ‘scientific absorptive 
capacity’, that is geared towards the absorption of state-of-the-art, academic expertise. 
Scientific absorptive capacity signals a firm´s scientific competence to the academic 
community, e.g. through publishing scientific papers, and facilitates firms’ abilities to get 
embedded and involved in the process of knowledge creation and knowledge exchange within 
the scientific community (Schmoch, 1997; Deeds and Hill, 1998). The build-up of scientific 
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absorptive capacity, however, requires long term investments in scientific research 
capabilities through the hiring of dedicated in-house scientists in order to bridge cognitive 
distance, and the adoption and implementation of specialised organizational practices in 
R&D, to bridge institutional distance to universities. This makes the build-up of scientific 
absorptive capacity a costly and complex process with pay-offs mostly expected in the longer 
term. Not every pharmaceutical firm commits itself to making these investments, and the 
degree of scientific absorptive capacity differs importantly across pharmaceutical firms 
(Gambardella, 1992; Fabrizio, 2009; Leten et al. 2011).1  
 
We argue that a strong scientific absorptive capacity enhances the relative effectiveness of 
direct university collaboration, whereas a relative lack of scientific absorptive capacity is 
associated with stronger performance consequences of indirect ties to universities. Our 
arguments and empirical tests specifically focus on the performance consequences of direct 
and DBF-mediated ties for vertically integrated pharmaceutical firms; biotechnology ventures 
are examined in their role as ‘brokers’ between university research and pharmaceutical firms. 
We test hypotheses on panel data (1995-2002) describing the innovation performance, R&D 
collaboration strategies, and scientific publication efforts of 33 pharmaceutical firms with 
their home base in the US, Europe and Japan.  
 
                                               
1 For instance, while Merck has always invested strongly in basic research and university 
collaboration, Pfizer tends to invest significantly less in scientific research. In our data, the 
ratio of Merck’s basic research publications to patents in the biopharmaceutical field is about 
50 percent higher than Pfizer’s, and about 10 times the ratio for Johnson and Johnson. 
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Our research contributes to the industry-science links literature and the strategic collaboration 
literature by examining direct and indirect collaboration as alternative means for firms to 
source scientific knowledge. We inform the literature on strategic R&D organization (e.g. 
Cassiman and Valentini, 2009; Tzabbar et al., 2008) by highlighting the role of firm 
heterogeneity in organizing for scientific absorptive capacity, and by suggesting how this 
affects firms´ ability to benefit from different collaboration strategies with universities in 
science-based industries. Our analysis of the role of scientific absorptive capacity furthermore 
contributes to the literature on absorptive capacity by bringing in greater precision on the 
construct. The focus on a particular type of absorptive capacity in the context of university 
collaboration allows us to detail what type of external knowledge gets absorbed and what type 
of capabilities are required for absorption - aspects that have received limited attention in 
prior research (Zahra and George, 2002; Volberda et al., 2010). 
 
Before proceeding, we note a number of caveats of our study. First, the empirical focus and 
data requirements of our analysis has restricted the number of firms included in the analyses 
to a limited number of large, vertically integrated pharmaceutical firms. Second, despite the 
use of multiple sources of information, it is likely that our data on direct university 
collaborations remains incomplete. Third, the difficulty in finding suitable instruments 
precluded controlling for potential endogeneity, such that we interpret the relationships under 
study as partial correlations. These issues suggest caution in the interpretation of our findings. 
We hope that future research can examine the generalizability of our findings in alternative 
empirical settings.  
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BACKGROUND AND THEORY 
 
Direct collaboration between firms and universities. In the life sciences and the 
biopharmaceutical industry, public science forms one of the key sources of rapid and 
privileged access to new, state-of-the-art knowledge (Cockburn and Henderson, 2000; Zucker, 
et al., 1998; Mowery, 1998). In general, direct collaboration with universities tends to be in 
more uncertain areas and further away from commercialization. Although new scientific 
knowledge gets disseminated through publications, an important part of it tends to be non-
codified and can only be exchanged through close interaction between individuals, through 
teams of university and firm scientists (Zucker et al., 1998; 2002; Cassiman et al., 2008). 
Tacit and sticky scientific knowledge can only be exchanged through direct links to the 
scientific community. Direct collaboration allows for the build-up of trust (Gulati, 1995a), 
which is an important prerequisite for the efficient exchange of tacit knowledge (Gilsing et 
al., 2008). Direct collaboration also reduces the likelihood of noise in information exchange 
and of fine-grained specificities getting lost, which mitigates the risk of misunderstanding 
(Ahuja, 2000).  
 
Direct collaboration with universities offers firms exposure to fundamental scientific expertise 
and enables them to better decode advances in fundamental research and evaluate its quality 
and usefulness. This provides firms with opportunities for recombination and may enable 
them to develop state-of-the-art technology that cannot be easily imitated by others (Cassiman 
et al., 2008). Direct collaboration can be instrumental in speeding up the transfer of frontier 
academic knowledge to the firm (Fabrizio, 2009), providing first mover advantages in applied 
research and leading to higher value inventions. Firms can learn early about the most 
promising research opportunities, such as ‘embryonic inventions’, at an early stage through 
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interaction with university inventors or through membership of broader scientific networks 
(Santoro and Gopalakrishnan, 2001; Colyvas et al. 2002; Hertzfeld et al., 2006). Embryonic 
inventions require substantial additional work, typically from the side of firms, before they 
become of any use and may turn into something with commercial value (Thursby et al., 2001; 
Carayol, 2003; Santoro and Betts, 2003). If investments by firms are required in the further 
development of these inventions in view of future commercialization, their bargaining 
positions relative to universities in obtaining property rights through patents will be stronger 
(Crespi et al., 2010). Direct collaboration in this way may secure early access to promising 
new technologies that have the potential to contribute most to a firm’s innovation 
performance.  
 
Firms that rely on direct collaboration with universities also have to cope with various kinds 
of barriers to knowledge exchange (Hall et al., 2001; Bruneel et al., 2010), which may 
mitigate the positive effects of direct collaboration with universities on a firm’s innovative 
performance. First, there can be a large cognitive distance between universities and firms 
(Nooteboom et al., 2007), as scientists’ focus on understanding fundamental problems and 
industrial researchers’ focus on application-related issues. As a consequence, these 
differences in cognition may create a risk that both parties do not sufficiently understand each 
other, with firms asking the ‘wrong’ knowledge questions and not being able to understand 
the answers they get, whereas scientists may misinterpret the questions or be unable to come 
up with an unequivocal answer (Gittelman and Kogut, 2003).  
 
In addition, the institutional logic of scientific discovery is different from the institutional 
logic that characterizes industrial development of new technologies and their practical 
applications. Science forms a separate ‘epistemic community’ with its own practices and 
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routines that conflict with the routines and practices in firms that are specifically geared 
towards the upscaling and commercialization of inventions (Allen, 1977; Tushman, 1977). 
Scientists tend to focus on research that is considered to be interesting and valuable by the 
scientific community, whereas firms will make choices based on what is considered to be 
useful for the creation of new products, processes and/or services (Gittelman and Kogut, 
2003; Nelson, 2004; Rothaermel and Deeds, 2006). University scientists will be keen on 
disclosing quickly in order to gain academic recognition and prestige, whereas industrial 
researchers may wish to keep information secret to facilitate value appropriation. Hence, 
institutional norms governing knowledge creation at universities differ profoundly when 
compared with firms. Such institutional distance may invoke a serious risk of opportunism as 
norms of reciprocity diminish if collaborating parties have incongruent goals and values 
(Deeds and Hill, 1998; Ouchi, 1980).  
 
Indirect ties between firms and universities. Indirect ties imply that a firm is indirectly 
connected to a university through a common partner (Gulati, 1995b). The literature on 
network ties suggests that indirect ties offer firms the benefit of reducing the amount of time, 
costs and resources to gather and assimilate external information (Granovetter, 1985; Ahuja, 
2000; Nahapiet and Ghoshal, 1998; Shane and Cable, 2002). More specifically, two 
advantages of indirect ties are identified, which we discuss in the context of firm-university 
linkages. 
 
First, indirect ties can serve as an information-gathering device (Freeman, 1991), giving firms 
access to information about recent technological developments and developments in state-of-
the-art scientific knowledge. Universities as indirect partners fulfill a ‘radar’ function by 
bringing broader information to the attention of the focal firm (Freeman, 1991; Ahuja, 2000). 
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Second, indirect ties can serve as an information-processing device (Leonard-Barton, 1984) 
helping firms to screens, absorb, filter and categorize new technological and scientific 
developments in a more efficient way (Ahuja, 2000). Given the large number of scientific 
discoveries in the life sciences, search costs for pharmaceutical firms run very high (Stuart et 
al., 2007). Indirect ties can support the identification, screening and classification of the most 
promising and relevant scientific findings. Although indirect ties operate by definition at a 
larger social distance in the firm’s network, the two-step reach may suffice in facilitating 
knowledge flows (Singh, 2003; Li and Rowley, 2002).  
 
The general advantages of indirect ties suggested in the literature are in line with the 
description of the role of DBFs as tie ‘brokers’ in the biopharmaceutical industry. DBFs 
originate from universities and public research organizations (PROs) and generally possess 
expertise in the development of novel scientific approaches to drug development (see e.g. 
Liebeskind et al., 1996; Audretsch & Stephan, 1996; Powell et al., 1996; Zucker et al., 1998; 
Zucker et al., 2002; George et al., 2002; Murray and Stern; Stuart et al., 2007). DBFs maintain 
broad and deep formal and informal relationships with universities, while they are often 
simultaneously collaborating with downstream pharmaceutical companies. The more DBFs 
embed linkages to university research while simultaneously engaging in joint development 
activities with other firms, the more technology they are able to ‘convey’ relevant scientific 
knowledge to these downstream alliance partners such as pharmaceutical companies (e.g. 
Powell et al., 2005; Gilsing and Nooteboom, 2006). It has therefore been suggested that DBFs 
can serve as effective brokers between universities and (large) pharmaceutical companies 
(Stuart et al., 2007).   
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Pharmaceutical firms may be better able to learn from universities through DBF-mediated ties 
because DBFs have compatible values and related operational priorities. For academic 
scientists, collaboration with DBFs remain attractive as they have sufficient absorptive 
capacity and are familiar with the norms and institutionalized practices in academia 
(Gittelman and Kogut, 2003). Hence, DBFs can act as intermediary organizations that tap into 
the knowledge and capabilities of academic scientists and manage the selection of scientific 
inventions in order to create commercially valuable technological innovations (Audretsch and 
Stephan, 1996). They may serve as value-added ‘liaisons’ by obtaining intellectual property 
from universities and then monetize this through exchange with downstream partners, often 
after considerable investments in subsequent development of the technology. Brokering is an 
attractive role for DBFs because the more agreements and collaborations they have with 
universities, the more they may be able to attract revenue-generating alliances with 
downstream partners (George et al., 2002; Stuart et al., 2007).  
  
The benefits of indirect ties notwithstanding, indirect ties also have drawbacks. Information 
obtained through indirect ties is imperfect and can be rather ‘noisy’ (e. g. Ahuja, 2000). It 
passes through a common partner, which may filter, interpret and attach meaning to this 
information in a different way than the focal firm would do. In this process, fine-grained 
specificities may fail to reach the focal firm. Furthermore, DBFs as the common-partner may 
obtain a powerful position if they can control the flows of information and resources between 
the focal firm and the indirect partner(s). This  may enable them to extract extraordinary 
returns (Burt, 1992) and to share valuable knowledge and insights selectively with the focal 
firm.  
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Still, these drawbacks of mediated ties to universities may be offset by the benefits of 
obtaining insights into unfamiliar domains and key scientific developments. In particular 
those pharmaceutical firms with little scientific research involvement will lack knowledge of 
such insights and their implications. 
 
Hypotheses. Based on the extant literature, it is evident that direct collaboration and indirect 
collaboration with universities are alternative strategies for firms to boost their innovation 
performance in a science-based industry. We argue that the extent to which one strategy 
provides more performance benefits than the other will vary among firms. We expect an 
important degree of heterogeneity in firms’ R&D strategy and organization, as prior research 
has shown that firms vary in their knowledge base profiles and their institutionalized practices 
and routines in R&D (D’Este, 2005; Bercovitz and Feldman, 2007; Cassiman et al., 2008; 
Cassiman and Gambardella, 2009). We argue that firms with a stronger focus on conducting 
basic research have a stronger capacity to absorb scientific knowledge and a better ability to 
bridge institutional distance with universities.  
 
An important aspect of a R&D organization is the degree to which firms place particular 
emphasis on basic research rather than focusing only on applied research and development 
(Rosenberg, 1990; Bercovitz and Feldman, 2007; Fabrizio, 2009). When firms place an 
emphasis on basic research, they may hire in-house scientists, provide corporate support for 
their publication efforts in scientific journals and encourage them to comply with the norms 
and institutionalized practices in academia (Gittelman and Kogut, 2003). Such an adaptation 
of a firm’s R&D organization focusing on the role of 'open science' and fundamental research 
may help firms to attract high quality researchers at relatively low cost (Stern, 1999) and 
provide legitimacy and reputation in the academic community. This may facilitate privileged 
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access to frontier developments in relevant academic fields (Cockburn and Henderson, 1998). 
In general, such an R&D organization contributes to the build-up of ‘scientific absorptive 
capacity’: the capacity to understand, assimilate and utilize scientific knowledge.        
 
The more a firm’s R&D organization is organized for accessing, analyzing and sharing state 
of the art scientific expertise - through own research activities, participation in academic 
conferences as well as through ongoing internal conversations and meetings between in-house 
scientists and applied researchers - the better it will be able to bridge cognitive distance with 
universities and develop a deeper understanding of the fundamental principles of the 
phenomena under study (Rosenberg, 1990; Orsenigo et al., 2001). Apart from bridging this 
cognitive distance, scientific absorptive capacity contributes to easier communication with 
university researchers and to bridging the institutional distance, providing legitimacy to the 
firm as a credible partner in basic research. Firm engaging in basic research will allow in-
house scientists to participate fully in the distinct epistemic community that science represents 
(Gittelman and Kogut, 2003; Nesta and Saviotti, 2005), e.g. by attending conferences and 
publishing papers, creating a higher degree of congruence of the goals and values between the 
two collaborating parties that provides the basis for the build-up of trust in the relationship 
(Deeds and Hill, 1998). The role of trust is important in any collaboration but crucial between 
two parties from different institutional spheres, as it reduces the risk of opportunism that may 
in particular be present in collaborations between people with different backgrounds and 
diverging interests (Ouchi, 1980). In addition, trust contributes to the exchange of tacit 
knowledge and may help to alleviate the risk of conflict over the distribution of intellectual 
property rights (Bruneel et al., 2010).  
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A key mechanism in this process is formed by in-house scientists who can perform a critical 
brokerage role. They can serve as external gate-keepers contributing to the build-up of 
potential absorptive capacity through the acquisition of key external scientific expertise as 
well as its interpretation and comprehension (Zahra and George, 2002). In-house scientists 
will be able to understand novel causal relationships, whereas they can also assess which 
trajectories may probably become dead-ends and which ones will be much more promising 
(Fleming and Sorenson, 2004). In this way, in-house scientists can also serve as internal 
gatekeepers who contribute to the build-up of realized absorptive capacity: the transformation 
and exploitation of external scientific expertise (Zahra and George, 2002). Realized 
absorptive capacity is created by in-house scientists who bridge the gap between a firm’s 
scientific and applied research activities, through their understanding of the potential 
implications for applied research and their use of heuristics that enable them to assess the 
likelihood of success of certain innovation trajectories (Cassiman and Valentini, 2009; 
Gambardella, 1992). This entails a transformation capability that ‘translates’ basic scientiﬁc 
ﬁndings into implications for applied research and future innovation opportunities in 
downstream markets, suggesting that capabilities in fundamental research may increase the 
effectiveness of applied research (Cassiman and Veugelers, 2006; Dasgupta and David, 
1994).  
 
Within the context of the bio-pharmaceutical industry, a ‘transformational’ capability helps to 
connect early basic research with clinical testing and includes activities such as target 
identiﬁcation and validation, in vitro and in vivo screening, and even early-stage human 
clinical trials (Pisano, 2006). Transformation is then followed by exploitation if firms develop 
high impact technologies (e.g. new molecular entities) building on more fundamental basic 
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research findings, materializing in the development of new and marketable innovations in 
downstream markets (Zahra and George, 2002; Cassiman et al., 2008). 
 
For firms with high scientific absorptive capacity, indirect collaboration with universities, 
through DBF mediated ties, is likely to have fewer advantages. Engagement in mediated ties 
may imply that firms miss out on key benefits of direct collaboration such as access to 
complementary expertise and skills, the possibility to keep up with major technological 
developments and achieve potential research synergies (Caloghirou et al., 2001) and access to 
embryonic inventions (Santoro and Gopalakrishnan, 2001; Colyvas et al. 2002; Hertzfeld et 
al., 2006). Indirect collaboration with universities may also imply that DBFs will be the party 
to get early access to embryonic inventions, and may be able to obtain the property rights of 
such university-developed technology earlier (Colyvas et al., 2002; Hertzfeld et al., 2006; 
Crespi et al., 2010). Scientific knowledge sourced through DBF mediated ties are also likely 
to be of a more general and noisier nature (Ahuja 2000; Vanhaverbeke et al., 2012), while 
firms with high scientific absorptive capacity can access and absorb more specialised and 
fine-grained scientific knowledge developed at universities through direct collaboration.   
 
The above arguments suggest that for firms with high scientific absorptive capacity direct 
collaboration with universities is more likely to be associated with improved innovation 
performance than DBF-mediated ties to universities. This leads to the following hypothesis: 
 
Hypothesis 1: For pharmaceutical firms with high scientific absorptive capacity, direct 
collaborative ties with universities have a stronger association with innovative performance 
than DBF-mediated ties with universities. 
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For firms with low scientific absorptive capacity, direct collaboration with universities is less 
likely to bring innovation benefits. These firms do not have a R&D organization that is well 
equipped to bridge institutional differences with academia and may lack the ability to 
effectively assimilate scientific knowledge. A lack of scientific absorptive capacity implies 
that bridging of both cognitive and institutional distance is beyond their capabilities. In 
addition, engagement in university collaboration will dislodge scarce resources from more 
fruitful applied research within these firms.  
 
Instead, for firms with low scientific absorptive capacity, DBF mediated ties are a good 
alternative to access scientific knowledge. DBF mediated ties to universities can serve both as 
a ‘cognitive bridge’ and ‘institutional bridge’, avoiding the need for fundamental adaptations 
to their R&D organization necessary for direct collaboration. For these pharmaceutical firms, 
it is the indirect connection with universities that contributes to the build-up of potential 
absorptive capacity as it serves as an external channel for both the acquisition of key scientific 
expertise as well as its assimilation through interpretation and comprehension by DBFs 
(Zahra and George, 2002). The direct connection with DBFs contributes to realized absorptive 
capacity, as this collaboration process involves ‘translating’ basic scientiﬁc ﬁndings into 
implications for applied research as well as their exploitation through application and 
incorporation into the pharmaceutical firm´s products and processes (Calantone et al., 2002; 
Lane and Lubatkin, 1998; Zahra and George, 2002).  
 
The strategy of DBF mediated ties to universities is consistent with the notion that brokerage 
between two unconnected partners is more valuable when behavioral norms and routines are 
more distant and that there is tacit knowledge involved (Hargadon and Sutton, 1997; Burt, 
2007). As universities and firms with low scientific absorptive capacity exhibit substantial 
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differences in their norms and institutionalized practices and as the exchange of tacit 
knowledge is involved, these conditions apply well in this context. It follows that DBF-
mediated ties are most likely to contribute to the innovation performance of firms with low 
scientific absorptive capacity, in comparison with direct university ties. This suggests the 
following hypothesis: 
 
Hypothesis 2: For pharmaceutical firms with low scientific absorptive capacity, DBF mediated 
ties with universities have a stronger association with innovative performance 
than direct collaborative ties. 
 
 
DATA AND EMPIRICAL METHODS 
 
Sample and Data. We constructed a panel dataset (1995-2002) on 33 of the largest EU, US 
and Japanese pharmaceutical firms. The focal firms are vertically integrated firms engaged in 
later stage trials and marketing as well as drug research and development. The firms were 
identified as applicants of biotechnology patents (see below) and listed on the 2004 EU 
Industrial R&D Investment Scoreboard, which contains the top 1000 R&D spending firms 
both in Europe and the rest of the world. We collected information on the firms’ patent 
applications at the European Patent Office (EPO) at the consolidated level, i.e. taking into 
account patents of the parent firms and all their consolidated (majority-owned) subsidiaries. 
We also collected information on the scientific publication efforts of the firms. We extracted 
publication data from Thomson Reuters Web of Knowledge, including peer-reviewed papers 
of the types article, letter, note and review. Alliance data were drawn from the CATI database 
(Hagedoorn, 2002) on strategic alliances as well as the RECAP (Recombinant Capital) 
database. The latter alliance database is a source on publicly announced alliances in the 
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biomedical field collected from press releases, SEC filings, and industry presentations. 
Information on branded and non-branded product sales and ongoing developments projects 
was extracted from the Pharmaceutical Industry Database (PhID) developed by Pammolli et al 
(2011). Finally, we collected accounting data from the Worldscope and Compustat databases. 
 
The focus on pharmaceutical firms and the combined data requirements imposed several 
sample screens on the data. We excluded non-integrated specialized biotechnology firms 
(DBFs) among the focal firms, as wells as firms chemical firms and firms focusing on 
instrument development. A number of larger European firms (e.g. Astra Zeneca, GSK) could 
not be included because they were involved in mergers during the period, hampering 
performance analysis over time, and for several firms no information was available in the 
Pharmaceutical Industry Database. This limited the sample for analysis to 33 firms based in 
the US, Europe and Japan, resulting in an almost balanced panel dataset with 248 
observations. Given the selection from the R&D scoreboard, R&D budgets of the firms tend 
to be large, amounting to several hundreds of million dollars in 2002 and with Pfizer investing 
more than 5 billion dollars in R&D in that year. Total 2002 R&D expenditures of the firms 
amounted to more than 31 billion US dollars.  
 
Variables and Measures. We measured the innovative performance of the sample firms (the 
dependent variable) in a particular year as the count of the number of forward patent citations 
received by the patents applied for by the firm in the biotechnology field in the year. We 
measured patent citations over a fixed time window of 5 years. This ‘weighting’ by the 
forward patent citations allows controlling for variation in the value and technological 
importance of patented inventions (Harhoff et al, 1999; Hall et al, 2005). Specifically in the 
context of drug development, recent research (Hiou et al., 2012; Magazinni et al., 2012) found 
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a strong relationship between patent citations and the later success (FDA approval) of the 
drugs that were developed based on the patented molecular entity. This suggests that patent 
citations can be seen as a ‘forward looking’ indicator of success in drug development.  
 
The key independent variables represent the number of direct collaborative and DBF-
mediated ties to universities. The number of direct R&D collaboration agreements with 
universities is calculated by drawing on the RECAP database on pharmaceutical 
collaborations, complemented with information from the Lexis Nexis database covering press 
releases, articles and reports related to the focal firms. We extracted the information from 
Lexis Nexis through text mining techniques, collecting those articles (press releases, trade 
journals, newspapers) covering the focal firms in the relevant timeframe and containing 
relevant keywords (university, R&D, collaboration). We subsequently read the selected 
articles to determine if these were reporting on research collaborations not yet covered in the 
RECAP data. Throughout, we focused on research collaborations and excluded licensing and 
other non-collaborative agreements, while limiting the count to alliances in the biotech field 
to maintain consistency with the focus of the dependent variable. In total, we identified 151 
direct collaborations between universities and the focal firms. 
 
We counted the number of active collaborations and ties in a year. We identified the first and 
final years of the period during which the agreements were valid if information was available. 
In case no information was available on the dissolution of agreements, the length of the 
agreement was assumed to be five years (Stuart, 2000; Lavie, 2007). Similarly, the number of 
mediated ties to universities brokered by dedicated biotech firms was measured as the number 
of research collaborations in biotechnology between universities and the DBF partners of the 
pharmaceutical firms – the latter identified in the CATI database.  
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We note that despite the use of multiple sources of data (RECAP as well as LEXIS NEXIS) 
the identification of research collaborations with universities is very likely to be incomplete. 
Furthermore, a limitation of our study is that we cannot take the differential importance and 
scope of the collaborations into account. We conducted additional analysis to assess the 
quality of the direct tie indicator. We used information drawn from the firms’ scientific 
publications to identify publications co-authored with university scientists, using string search 
algorithms. The information drawn from copublications broadly confirmed the accurateness 
of the collaborations included in the analysis: close to 90 percent of the direct ties to 
universities could be traced in copublications between the firm and university. At the same 
time, the copublications identified a range of other research linkages between firms and 
universities. In auxiliary analysis, we explored an augmented direct collaboration measure 
that also drew on copublication data. We required that published coauthored research focused 
on basic research and included multiple (a minimum of 5) copublications – to assure 
systematic research collaboration of some scope. This resulted in close to 125 additional ties 
that could be included in the new direct collaboration variable. Despite this substantial 
increase, the new variable was highly (83 percent) and significantly correlated with the 
original variable. Substituting the new variable, in addition to a corresponding new top-20 
university variable, in the estimating models produced similar results as those reported in the 
paper below.  
 
The key moderator variable in our analysis is a firm's scientific absorptive capacity. It is 
measured as the number of basic scientific publications on which the firm or its subsidiaries 
are listed as the affiliations of one of the authors in a prior 4-year period. Engagement in in-
house scientific research as evidenced by scientific publications is a clear indication of the 
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presence of in-house scientists and an R&D organization facilitating the absorption and 
utilization of scientific knowledge (e. g. Gambardella, 1992; Cockburn and Henderson, 1998).  
To ensure that we measure in-house absorptive capacity and in order to avoid potential 
overlap with the collaboration variable, we limit the publications to those that do not list 
universities as collaborating institutions.  
 
Furthermore, we focus on publications that can be regarded as ‘basic’ research, rather than 
publications that reflect the results of clinical trials. Engagement in basic research is closely 
aligned with the concept of scientific absorptive capacity as it measures the involvement in 
scientific discovery. Among scientific articles in the ISI database, a large share report on 
applied research activities, which in the context of the pharmaceutical sector relates to clinical 
trials (Hicks, 1994). Using information on the journals in which firms’ scientific articles are 
published and the CHI classification scheme for basic versus applied research (Hamilton, 
2003), we constructed the indicator by focusing on the subset of scientific articles appearing 
in journals that are classified as reporting mainly on basic scientific research. The CHI 
classification, which was prepared for the National Science Foundation, distinguishes four 
research Levels in biomedical research: 1: Clinical Observation; 2: Clinical Mix; 3: Clinical 
Investigation; 4:  Basic Biomedical Research. The scientific absorptive capacity variable 
includes level 4 publications only. Finally, we scaled the number of publications by the 
number of prior patent applications to ensure that it is reflective of the orientation towards 
scientific research of the firms' R&D activities. 
 
One concern regarding the collaboration variables is that there is heterogeneity in the ‘quality’ 
of the university partners that may affect innovation outcomes. We therefore included a 
variable measuring what share of direct and mediated ties, respectively, is with universities 
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listed in the top 20 of publishing universities in the relevant domain.2 We collected data on the 
number of publications in relevant fields (biosciences, general and internal medicine, medical 
specialties, biomedical research, chemistry) during the period of investigation. We accessed 
Thomson Reuters Web of Knowledge and extracted the number of publications of these 
universities that we identified as direct or indirect partners. The top publishing institutions 
were Harvard University, University College London, University of Tokyo, John Hopkins, 
University of Toronto, University of Washington, UCLA, UC San Francisco, University of 
Pennsylvania, and Imperial College. Other universities in the top 20 include Stanford, Yale, 
and Ludwig Maximilian University (Berlin). 
 
We include a set of time-variant firm characteristics that are likely to affect the innovative 
performance of firms. We control for a firm’s research and development expenditures in the 
biotechnology field in the past year, since the technological performance of firms is 
influenced by the amount of capital invested in R&D activities. As data on R&D expenditures 
dedicated to biotechnology is not available, we approximate the relevant R&D input by 
multiplying a firm’s total R&D expenditures by the share of its biotechnological activity in its 
overall portfolio of technological activities. The importance of biotechnology activity is 
approximated by the share of biotechnology patents in the total number of the firm’s patents. 
The variable is taken in natural logarithm.  
 
The analysis also controls for potential differences across firms in the propensity to patent (at 
the European Patent Office) by including the ratio of patents to R&D expenditures. The 
                                               
2 Applying a top 10 criterion produced comparable empirical results. 
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number of inter-firm R&D alliances, or precisely, the number of cooperative research 
agreements in the biotech field with partner firms that are not collaborating directly on 
biotech research with universities, is added to the models to control for the influence of inter-
firm technology alliances.  
 
Two other variables are introduced to control for other aspects of firm heterogeneity: a 
dummy variable indicating whether the firm has non-branded products on sale as an indicator 
of the firm’s involvement in generic drugs, and a variable indicating the share of the firm’s 
drug development projects that reached Phase III of clinical trials. The latter variable may 
have a negative association with innovation performance if the absence of a pipeline of drugs 
nearing approval and market introduction puts additional pressure on pharmaceutical firms to 
develop new promising compounds with promising applications. On the other hand, the 
presence of a strong pipeline may indicate unobserved heterogeneity in drug development 
expertise.  
Finally, the models include the main effect of scientific absorptive capacity, year dummies to 
account for time-specific factors that may affect the number of firms’ patents and citations, 
and fixed effects to control for time-invariant firm traits. Explanatory variables are measured 
(one year) prior to the dependent variable.  
 
Summary statistics and correlations for the variables are provided in Table 1. The descriptives 
distinguish between ‘low’ scientific absorptive capacity firms and ‘high’ scientific absorptive 
firms, based on the median value of scientific absorptive capacity in the sample. The 
descriptives show that on average direct collaboration with universities is more common for 
high scientific absorptive capacity firms, while the average number of indirect ties is larger 
for low scientific absorptive capacity firms, although these differences are not overwhelming. 
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High scientific absorptive capacity firms only have a slightly higher share of top publishing 
universities among their direct collaborations, while indirect ties with top universities are 
slightly more common among low scientific absorptive capacity firms. Average R&D 
expenditures are roughly equal across samples. The major difference, naturally, is in scientific 
absorptive capacity, reaching a ratio of 2,45 publications over patents for high scientific 
absorptive capacity firms, versus 0,8 for low scientific absorptive capacity firms. The 
coefficients of correlation between the independent variables are moderate and do not suggest 
multicollinearity concerns.  
-------------------------------- 
Insert Table 1about here 
--------------------------------- 
 
Methods. Since the dependent variable takes non-negative integer values, nonlinear count 
data models, such as Poisson or Negative Binomial specifications, are preferred over linear 
regression models as they explicitly take into account the non-negativity and discreteness of 
the dependent variable. The LR test for the assumption of the Poisson model that the variance 
of the dependent variable equals its mean (e.g. Cameron and Trivedi, 2008) rejected the null 
hypothesis that the dispersion parameter is equal to zero at the 1 percent level. We therefore 
employ negative binomial models that allow for overdispersion and generate efficient 
estimates. A concern with negative binomial models is that the specific modelling of the 
variance does not guarantee consistent estimates. We examined the potential bias in the 
estimates by conducting a test for equality of the coefficients obtained from the fixed effects 
negative binomial model and the fixed effects Poisson model. We could not reject the null 
hypothesis that the coefficients on the focal variables obtained via the two models were equal.  
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We conducted split sample analysis to investigate the heterogeneous effects of alliances for 
firms with different levels of scientific absorptive capacity. We divided the sample into two 
subsamples: firms with high and firms with low scientific absorptive capacity. For the 
division of the sample we used the median value of the firms’ scientific absorptive capacity as 
cutoff point.3 Hypotheses 1 and 2 are then tested by examining the coefficients for mediated 
collaborative ties and direct university collaboration for each subsample. We employed a 
‘split sample’ analysis rather than including interaction terms for scientific absorptive 
capacity because a split sample analysis is the more general test specification when comparing 
coefficients between groups of observations (Hoetker, 2007). A split sample test does not 
assume that unexplained variance is identical between the two groups of firms (with high or 
low scientific absorptive capacity) and also allows for the impact of other characteristics to 
differ systematically between the groups, which leads to consistent within-group estimates. In 
this case, we preferred not to assume that all other determinants of innovative performance are 
equal between high and low absorptive capacity firms. 
 
Although the models include a broad set of controls variables, we cannot exclude the 
possibility of unobserved heterogeneity resulting in endogeneity bias. Given the difficulty of 
finding a proper set of instruments for the collaboration variables to test and control for 
                                               
3 This ensures a roughly equal number of observations in the subsamples, but otherwise 
remains an arbitrary categorization. We return to this issue in the supplementary analysis 
section. 
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endogeneity, we cannot claim that our analysis establishes causality. Hence, we interpret the 
estimates as partial correlations.  
 
EMPIRICAL RESULTS 
The results of the fixed effects Negative Binomial Analysis relating firms’ innovative 
performance to their collaboration strategies are presented in Table 2. Models 3 and 4 report 
the results for high scientific absorptive capacity firms and models 5 and 6 for low scientific 
absorptive capacity firms. For comparison, baseline models on the full sample reported in 
models 1 and 2. The first of each of these model pairs is a baseline model with control 
variables only.  
 
The full sample model 1 shows positive and significant coefficients of engagement in inter-
firm alliances, R&D expenditures, patent propensity, and scientific absorptive capacity, while 
the share development projects in Phase III is associated with reduced innovative 
performance. Adding the direct and mediated tie variables in model 2, the coefficient on 
mediated ties is significantly positive, but no significant association is found between direct 
university ties and innovation performance. This pattern changes markedly if we split the 
sample into two groups based on firms’ scientific absorptive capacity.  
 
For high scientific absorptive capacity firms, the coefficient on direct collaboration with 
universities is positive and significant effect (model 4), while the coefficient on mediated ties 
also is positive and significant (at the 10 percent level). For low scientific absorptive capacity 
firms, indirect ties to universities have a significantly positive association with innovative 
performance, whilst the coefficient on direct collaboration is negative but insignificant. For 
high absorptive capacity firms, a t-test on the equality of the coefficients for mediated ties and 
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direct ties reject the null hypothesis of equality (a p-value 0.07), in support of Hypothesis 1. 
Hypothesis 2, however, finds no support: although the coefficients between mediated ties and 
direct collaboration have opposite signs and the coefficient on mediated ties is significant at 
the 5 percent level, a t-test cannot reject equality of coefficients. This is due to the substantial 
imprecision with which the coefficient on direct collaboration is estimated.  
 
The coefficients on the share of top universities in the collaboration portfolio of firms are 
generally not significant, with one exception: the share of top universities among mediated tie 
partners is negative and significant for low scientific absorptive capacity firms, mitigating the 
positive association between mediated ties and innovation performance. This effect is 
relatively strong: The coefficients suggest that the positive implications of mediated ties 
disappear if about one quarter of these are with top universities. We return to this finding in 
the discussion. 
-------------------------------- 
Insert Table 2 about here 
--------------------------------- 
Given that the expected value of the dependent variable in the Negative Binomial 
model is ܧ(ݕ) = ܧݔ݌(ܾܺ), the coefficients b represent the pseudo elasticity of innovative 
performance (the number of citation weighted patents) with respect to the independent 
variables. The pseudo elasticity is the proportional increase in innovative performance due to 
a one unit increase in the independent variables. Hence, the coefficient on direct ties in model 
4 suggests that an additional direct university tie is associated with a performance increase of 
14 percent for high scientific absorptive capacity firms. For low scientific absorptive capacity 
firms (model 6), an additional indirect tie is associated with a 2,3 percent increase in 
performance.  
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Supplementary analysis. We examined differences between high and low scientific 
absorptive capacity firms by separating firms at the sample median. The median value to split 
the sample is a focal point given the limited number of firms we have in our sample and a 
desired balance in degrees of freedom across subsamples. Requiring lower or higher 
thresholds than the median leads to an imbalance in sample size, such that insignificant 
findings could also be due to the limited degrees of freedom. We experimented with 
thresholds for the sample split defining high scientific absorptive capacity firms in a more 
stringent or less stringent manner. The possibility to do so is limited as the number of firms in 
one of the subsamples quickly reduces to less than 10. While broadening the group of firms in 
a subsample generally gave consistent but somewhat weaker results, a smaller number of 
firms in the subsamples resulted in insignificance of the collaboration variables, suggesting 
that the models suffer from imprecision in the estimates due to the reduced degrees of 
freedom. We conclude that the relatively limited empirical base prevents us from gaining 
clear insight into the level of scientific absorptive capacity at which the relative benefits of 
direct and mediated ties occur. 
 
 
DISCUSSION AND CONCLUSION 
In the literature, two different views on firm - university collaboration co-exist. In the 
industry-science literature the importance of direct collaboration between firms and 
universities, particularly in knowledge-intensive industries, is endorsed (Cohen et al., 2002; 
Zucker and Darby, 2001; Zucker et al., 2002; Zucker and Darby, 2002). On the other hand, in 
the innovation and strategic alliance literature the role of brokerage through DBFs as 
specialized go-betweens is emphasized (Powell et al., 1996; George et al., 2002; Pisano, 
1991; Stuart et al., 2007). Despite their different emphasis, both streams of research tend to 
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regard pharmaceutical firms implicitly as possessing similar in-house resources and 
capabilities to absorb state-of-the-art, scientific expertise, i.e. as possessing similar ‘scientific 
absorptive capacity’. Our findings suggest that this assumption of homogeneity may not hold 
among vertically integrated pharmaceutical firms.  
 
We found substantial heterogeneity in the importance of in-house scientific research among 
pharmaceutical firms (our indicator of scientific absorptive capacity). This heterogeneity was 
associated with differences in the performance consequences of direct university collaboration 
and DBF-mediated ties. Specifically, for firms with relatively high scientific absorptive 
capacity, the association between direct collaboration and innovation performance was 
significantly stronger than the association between mediated ties and performance. For firms 
with more limited scientific absorptive capacity only mediated ties were significantly 
associated with performance - although the relative imprecision of estimates lent no support 
for the hypothesis that the association between performance and mediated ties was stronger 
than the association between performance and direct ties.  
 
Our empirical findings on the influence of the scientific strength of the universities with 
which firms maintain direct or mediated ties were mixed. We did not observe a significant 
association between innovation performance and the academic strength of universities with 
which the focal firms established direct collaborations. In contrast, for low scientific 
absorptive capacity firms, the association between mediated ties and innovation performance 
was importantly diminished when firms connect to top research universities. An explanation 
for the latter finding is that even mediated ties, when they connect to state-of-the-art scientific 
research at top universities, may still confront low scientific absorptive capacity firms with 
cognitive and institutional obstacles to benefit from these ties, such that resources allocated to 
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these collaborations reduce overall effectiveness of the R&D and knowledge sourcing strategy 
of the firm (Rothaermel and Deeds, 2006). It is conceivable that DBFs involved in 
collaboration with top institutions are closer to basic science and perhaps less able to perform 
their mediation and ‘translation’ function. In this regard, one aspect lacking in our analysis is 
the specific role the mediators (DBFs) and their characteristics play in the effectiveness of the 
mediated tie. In general, examining the role of mediator characteristics presents itself as an 
interesting avenue for future research.  
 
Our study is subject to a number of limitations suggesting that we have to interpret our 
findings with caution. It is likely that our measures of direct and indirect ties are incomplete 
and do not identify all (indirect) ties between firms and universities. In addition, the limited 
sample size of 33 firms may prevent capturing pharmaceutical firms’ heterogeneity regarding 
their scientific absorptive capacity in full. Both factors may play a role in the lack of precision 
in the estimate on direct ties for low absorptive capacity firms. The restricted empirical base 
also prevented us from gaining clear insight into the level of scientific absorptive capacity at 
which the relative benefits of direct and mediated ties occur, and limit the generalizability of 
our findings. Finally, our research is suggestive of associations between firm characteristics, 
collaboration strategies and innovation performance, but does not establish causal 
relationships. 
 
With these caveats in mind, collectively our findings are suggestive of the importance of a 
‘fit’ between the nature of a firms’ R&D organization and its collaboration strategy to access 
scientific knowledge. The existence of an alternative strategy to source scientific knowledge 
through indirect ties appears an overlooked issue in the industry-science literature and 
counters the common idea that in science-based industries, one should be proximate to, and 
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collaborate directly with public research organizations (Zucker and Darby, 2001; Zucker et 
al., 2002; Arundel and Geuna, 2004; Cassiman et al., 2008). Vertical specialization in the 
biopharmaceutical industry and the importance of DBFs in basic scientific research in close 
collaboration with universities provides pharmaceutical firms with an alternative route to 
benefit from scientific developments, without emphasizing investments in a science-oriented 
R&D organization.   
 
Our research provides reflections on the still poorly understood relationship between the 
process of absorptive capacity and interorganizational networks (Volberda et al., 2010). Our 
findings are consistent with the notion that firms with high scientific absorptive capacity can 
rely on in-house scientists to perform a critical brokerage role by serving as external gate-
keepers, contributing to the build-up of potential absorptive capacity (i.e. the acquisition and 
assimilation of key external scientific expertise) and as internal gate-keepers, contributing to 
the build-up of realized absorptive capacity (i.e. transformation and exploitation of key 
external scientific expertise). Firms with low scientific absorptive capacity externalize the 
absorption process through DBF mediated ties, while their collaboration with and the 
‘translation function’ of the DBF is likely to enhance the creation of realized absorptive 
capacity (Zahra and George, 2002). The literature on absorptive capacity until now has 
focused on the different steps in the absorption process, such as recognizing, assimilating and 
applying external knowledge (Cohen and Levinthal, 1990) or the sequence of potential and 
realized absorptive capacity (Zahra and George, 2002). A clear understanding of what specific 
kind of knowledge gets absorbed, and what constitutes the specific capabilities to absorb this 
particular knowledge is much less developed (Volberda et al., 2010). Here we contribute by 
focusing on the absorption of scientific knowledge that requires critical in-house scientific 
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capabilities as reflected by the degree to which firms’ researchers are conducting basic 
scientific research independently.   
 
Our study informs the literature on strategic R&D organization by highlighting the role of 
firm heterogeneity in organizing for scientific absorptive capacity, and how this affects firms´ 
ability to benefit from different collaboration strategies with universities in science based 
industries. Earlier studies have demonstrated that capabilities in basic R&D are associated 
with synergies between in-house R&D and external technology acquisition such as licensing 
and technology acquisition (Cassiman and Veugelers, 2006; 2009; Hagedoorn and Wang, 
2012). Our results align with the notion that a choice for a particular organization of R&D 
will have important consequences for the effectiveness of different external knowledge 
sourcing strategies (e.g. Cassiman and Valentini, 2009) and that firms should strive for 
complementarity between internal R&D resources and capabilities, and alternative external 
collaboration strategies (Tzabbar et al., 2008; Rothaermel and Alexandre, 2009). 
 
As noted above, the limitations of the current study suggest that more research is needed on 
the relationships between scientific absorptive capacity and direct and mediated ties to 
universities to establish the generalizability of our findings. Such research preferably focuses 
on a larger and more varied set of focal firms, while exploring more refined measures of 
collaboration. An interesting question is whether generalization is possible to other industries 
to the extent that these are also characterized by a key role of public research in industrial 
innovation and the presence of intermediary firms. Examples of this may be formed, among 
others, by microelectronics, advanced materials and nanotechnology (Lavie and Drori, 2011; 
Baba et al., 2009). Replication and extension of this type of study on (in)direct R&D 
collaboration with universities in other sectors and for broader sets of firms will help build 
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more insights into the importance of the various types of research collaborations and the 
influence of public research on firms’ innovation performance.  
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Table 1. Descriptive statistics and correlations 
 
 
 
 
High scientific absorptive capacity Mean Std. Dev. 1 2 3 4 5 6 7 8 9 10
1 Citation Weighted Biotech Patents (DV) 23,90 28,79
2 Direct University Collaborations 0,70 1,06 0,54
3 Mediated University Ties 4,74 6,84 0,54 0,22
4 Top20 Univ Share in Direct University Collaborations 2,25 6,69 -0,01 0,35 0,13
5 Top20 Univ Share in Mediated University Ties 3,47 9,12 0,02 0,04 0,20 0,28
6 Inter-firm Collaborations 6,04 6,35 0,58 0,57 0,50 0,10 0,02
7 Biotech R&D Expenditures 4,89 1,19 0,39 0,29 0,53 0,13 0,04 0,54
8 Patent Propensity 0,09 0,06 0,19 0,04 0,01 0,17 -0,05 0,09 -0,12
9 Scientific Absorptive Capacity 2,45 1,11 -0,16 -0,07 -0,22 -0,09 0,04 -0,25 -0,10 -0,34
10 Phase 3 Development Projects Share 0,12 0,07 -0,22 -0,15 0,00 0,09 -0,01 -0,17 -0,07 -0,14 0,22
11 Generic Drug Sales (Dummy) 0,69 0,46 0,22 0,01 0,39 -0,09 -0,10 0,40 0,34 0,15 -0,38 -0,31
Low scientific absorptive capacity Mean Std. Dev. 1 2 3 4 5 6 7 8 9 10
1 Citation Weighted Biotech Patents (DV) 31,37 37,67
2 Direct University Collaborations 0,51 0,82 0,16
3 Mediated University Ties 5,78 9,45 0,49 0,18
4 Top20 Univ Share in Direct University Collaborations 2,19 6,30 0,09 0,49 0,13
5 Top20 Univ Share in Mediated University Ties 4,78 10,71 0,05 -0,14 0,23 -0,13
6 Inter-firm Collaborations 6,74 7,61 0,51 0,45 0,64 0,23 0,06
7 Biotech R&D Expenditures 4,87 2,34 0,29 0,19 0,18 0,11 0,01 0,48
8 Patent Propensity 0,17 0,15 -0,03 -0,19 -0,21 -0,15 -0,16 -0,33 -0,35
9 Scientific Absorptive Capacity 0,81 0,43 0,35 0,27 0,17 0,22 0,08 0,35 0,41 -0,25
10 Phase 3 Development Projects Share 0,12 0,13 -0,09 -0,11 0,06 -0,04 -0,04 -0,08 0,14 -0,08 -0,04
11 Generic Drug Sales (Dummy) 0,45 0,50 0,31 0,38 0,33 0,25 -0,06 0,57 0,52 -0,43 0,47 0,35
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Table 2. Results of fixed effects negative binomial models of the innovative performance of pharmaceutical firms, 1995-2002
 
 
Notes: Standard errors in parentheses, * p<0. 1, ** p<0. 05, *** p<0. 01
Model 1 Model 2 Model 3 Model 4 Model 5 Model 6
Direct University Collaboration 0.0511 0.1401** -0.0172
(0.0621) (0.0714) (0.1167)
Mediated University Ties 0.0161** 0.0174* 0.0231***
(0.0068) (0.0104) (0.0084)
Top20 Univ Share in Direct University Collaborations 0.0018 -0.0082 -0.0014
(0.0077) (0.0103) (0.0115)
Top20 Univ Share in Mediated University Ties -0.0109* -0.0064 -0.0190**
(0.0058) (0.0079) (0.0083)
Inter-firm Collaborations 0.0271** 0.0228** 0.0582*** 0.0512*** 0.0129 0.0055
(0.0111) (0.0114) (0.0170) (0.0184) (0.0152) (0.0160)
Biotech R&D Expenditures 0.0861* 0.0825 0.0521 0.0409 0.2401** 0.2900**
(0.0501) (0.0508) (0.0712) (0.0732) (0.1016) (0.1134)
Patent Propensity 1.4290** 1.4870** 5.9890*** 6.0473*** 0.2614 0.1849
(0.6584) (0.6596) (0.9018) (0.9687) (0.8542) (0.8841)
Scientific Absorptive Capacity 0.3226*** 0.3370*** 0.3053*** 0.2909*** 0.3916 0.3696
(0.0814) (0.0869) (0.0974) (0.1060) (0.2740) (0.2712)
Phase 3 Development Projects Share -0.8922 -1.1560** -1.7559* -1.5880* 0.1461 -0.0349
(0.5585) (0.5724) (0.9012) (0.9032) (0.6994) (0.6842)
Generic Drug Sales (Dummy) 0.0621 0.0832 0.0206 0.1375 -0.2424 -0.2069
(0.1886) (0.1895) (0.3423) (0.3510) (0.2521) (0.2371)
Year Dummies Included Included Included Included Included Included
Constant -0.1358 -0.1450 0.1035 0.0676 -0.6516 -0.7444
(0.3904) (0.3899) (0.5854) (0.5842) (0.6832) (0.7182)
No. of Observations 248 248 127 127 121 121
No. of Firms 33 33 17 17 16 16
Log Likelihood -722.16 -717.48 -333.17 -330.37 -372.00 -366.53
Wald Chi-sqare 75.74*** 86.65*** 87.12*** 97.21*** 40.97*** 56.98***
Full Sample High Scientific Low Scientific
 Absorptive Capacity Firms  Absorptive Capacity Firms
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